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The advent of second generation antipsychotic drugs is
nowadays considered as a hallmark in the history of psy-
chopharmacology. The clinician treating psychotic disor-
ders is today “backed” by guidelines which present as a
first choice drug one belonging to the group of second
generation antipsychotics. Certainly the so called “second
generation group antipsychotics” present a dauntly inter-
esting side effects profile, where compared with the con-
ventional antipsychotic group, notably on aspects such as
EPS, higher efficacy in the treatment of negative symp-
toms and raise hopes in coping with an alleged cognitive
deficit related with the psychotic disorder. Yet the first
enthusiasm with which clinicians encompassed the use of
the “group” soon gave place to a certain skepticism. Side
effects such as weight gain, diabetes and dyslipidemia,
previously neglected in clinical practice and absent in clin-
ical literature started to concern clinicians in relation with
the use of the “new” drugs.
The new field of concern about the so called “metabolic”
side effects of the new antipsychotic drugs, sometimes
referred under the label “metabolic syndrome” becomes
more obscure by several questions which still remaining
open. First, there is preliminary evidence that such side
effects do not apply to the same degree to the “second gen-
eration antipsychotics” as a group but there are consider-
able within the group differences. Second, the relation to
the conventional antipsychotics with metabolic side
effects is characterized by a striking lack of relevant litera-
ture and research. Third, the psychotic procedure and
direct metabolic consequences have never been answered
in a satisfactory way.
Even the relatively newly introduced concept of the “met-
abolic syndrome” has recently been under scientific scru-
tiny. It represents a real syndrome per se, or a mere cluster
of individual risk factors and finally a “construction”? On
the other hand relevant studies give good evidence that a
large percentage of psychiatrists in their everyday practice
refrain from a more detailed examination of the general
medical condition of their patients. Perhaps such an atti-
tude is rooted in a long standing mentality of psychiatrists
that “medical problems” are concerns and should be
referred to general physicians.
The vicious circle raising from such attitudes, given the
fact that psychotic patients for reasons directly related
with their illness, have less access and obtain less medical
attention than the general population, led several scien-
tific associations to propose recommendations addressing
the psychiatric community. Such recommendations refer
mainly to the long term side effects of the “new” antipsy-
chotic drugs in the hope that such alert will lead to a more
comprehensive monitoring of the psychotic population.
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